Show simple item record

dc.contributor.authorKim, Jana
dc.contributor.authorMoestue, Siver Andreas
dc.contributor.authorBathen, Tone Frost
dc.contributor.authorKim, Eugene
dc.date.accessioned2019-09-24T07:43:40Z
dc.date.available2019-09-24T07:43:40Z
dc.date.created2019-09-23T11:50:41Z
dc.date.issued2019
dc.identifier.citationTomography. 2019, 5 (3), 308-319.nb_NO
dc.identifier.issn2379-1381
dc.identifier.urihttp://hdl.handle.net/11250/2618367
dc.description.abstractEffective transverse relaxivity of gadolinium-based contrast agents is often neglected in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Here, we assess time and tissue dependence of R2* enhancement and its impact on pharmacokinetic parameter quantification and treatment monitoring. Multiecho DCE-MRI was performed at 7 T on mice bearing subcutaneous TOV-21G human ovarian cancer xenografts (n 8) and on the transgenic adenocarcinoma of the mouse prostate (TRAMP) model (n 7). Subsequently, the TOV-21G tumor-bearing mice were treated with bevacizumab and rescanned 2 days later. Pharmacokinetic analysis (extended Tofts model) was performed using either the first echo signal only (standard singleecho DCE-MRI) or the estimated signal at TE 0 derived from exponential fitting of R2* relaxation (R2*- corrected). Neglecting R2* enhancement causes underestimation of Gd-DOTA concentration (peak enhancement underestimated by 9.4%–16% in TOV-21G tumors and 13%–20% in TRAMP prostates). Median Ktrans and ve were underestimated in every mouse (TOV-21G Ktrans: 11%–19%, TOV-21G ve: 5.3%–8.9%; TRAMP Ktrans: 8.6%–19%, TRAMP ve: 12%–21%). Bevacizumab treatment reduced Ktrans in all TOV-21G tumors after 48 hours. Treatment effect was significantly greater in all tumors after R2* correction (median change of 0.050 min1 in R2*-corrected Ktrans vs. 0.037 min1 in uncorrected Ktrans). R2* enhancement in DCEMRI is both time- and tissue-dependent and may not be negligible at 7 T in tissue with high Ktrans. This has consequences for the use of Ktrans and other DCE-MRI parameters as biomarkers, because treatment effect size can be underestimated when R2* enhancement is neglected.nb_NO
dc.language.isoengnb_NO
dc.publisherGrapho Publicationsnb_NO
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleR2* Relaxation Affects Pharmacokinetic Analysis of Dynamic Contrast-Enhanced MRI in Cancer and Underestimates Treatment Response at 7 Tnb_NO
dc.typeJournal articlenb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber308-319nb_NO
dc.source.volume5nb_NO
dc.source.journalTomographynb_NO
dc.source.issue3nb_NO
dc.identifier.doihttps://doi.org/10.18383/j.tom.2019.00015
dc.identifier.cristin1727740
dc.description.localcode© 2019 The Authors. Published by Grapho Publications, LLC This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)nb_NO
cristin.unitcode194,65,25,0
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for sirkulasjon og bildediagnostikk
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextoriginal


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal